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Abstract 
Background: The use of statins for primary prevention of cardiovascular diseases is associated with different ben-
efit and harm outcomes. The aime of this study is how important these outcomes are for people and what people’s 
preferences are.
Methods: We conducted a preference-eliciting survey incorporating a best–worst scaling (BWS) instrument in Iran 
from June to November 2019. The relative importance of 13 statins-related outcomes was assessed on a sample of 
1085 participants, including 913 general population (486 women) and 172 healthcare providers from the population 
covered by urban and rural primary health care centers. The participants made trade-off decisions and selected the 
most and least worrisome outcomes concurrently from 13 choice sets; each contains four outcomes generated using 
the balanced incomplete block design.
Results: According to the mean (SD) BWS scores, which can be (+ 4) in maximum and (− 4) in minimum, in the gen-
eral population, the most worrisome outcomes were severe stroke (3.37 (0.8)), severe myocardial infarction (2.71(0.7)), 
and cancer (2.69 (1.33)). While myopathy (− 3. 03 (1.03)), nausea/headache (− 2.69 (0.94)), and treatment discontinua-
tion due to side effects (− 2.24 (1.14)) were the least worrisome outcomes. Preferences were similar between rural and 
urban areas and among health care providers and the general population with overlapping uncertainty intervals.
Conclusion: The rank of health outcomes may be similar in various socio-cultural contexts. The preferences for ben-
efits and harms of statin therapy are essential to assess benefit-harm balance when recommending statins for primary 
prevention of cardiovascular diseases.
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Background
Cardiovascular diseases contribute to over 30% of deaths 
worldwide and more than 40% in Iran [1, 2]. Given that 
the raised total cholesterol and low-density lipoprotein 
(LDL) cholesterol are the major risk factors for cardiovas-
cular disease (CVD), controlling hypercholesterolemia is 
an important target in managing CVD risk [3]. Statins 
are a class of lipid-lowering drugs that have been widely 
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used for reducing the level of plasma LDL cholesterol [4]. 
Statins are widely prescribed for the primary and second-
ary prevention of CVD [5, 6], and their use has been sig-
nificantly increased over the last 30 years [7].
The various harm and benefit outcomes that are asso-
ciated with using statins have been reported in previous 
studies [8–10]. Shared decision-making is a process in 
which patients and physicians work together to make the 
best decision for health care, especially when treatments 
have different benefit and harm outcomes [11]. Statin 
therapy is a crux for primary prevention of CVD, and 
its prescription is a preference-sensitive decision [12]. 
Guidelines provide tools for risk calculation and decision 
thresholds for preventive drug therapy and recommend 
shared decision for borderline CVD risks [13, 14]. Peo-
ple value the benefit and harm outcomes of statins differ-
ently. This study aimed to elicit the preferences for these 
benefits and harms in different settings, including rural 
and urban areas and among healthcare providers and 
the general population. We used the best–worst scaling 
technique to elicit preferences; it is a popular method in 
health for its cognitive and administrative simplicity [15].
Methods
We conducted a preference-eliciting survey incorporat-
ing a best–worst scaling (BWS) instrument in Iran from 
June to November 2019. The best–worst scaling method 
was devised by Finn and Louviere [16] and introduced 
to healthcare research by McIntosh and Louviere [17]. 
In this method, choice sets are constructed by combin-
ing various items and then asking respondents to select 
the best and worst items from each choice set. Accord-
ing to the choice sets format, BWS is divided into three 
types: the object case, the profile case, and the multi-pro-
file case [18, 19]. Because in the present study, our pur-
pose was to measure the individual preferences, we used 
object case, which is suitable for perceiving the relative 
evaluation of the multiple items the respondents chose.
Questionnaire design and procedure
In the object case BWS—or maximum difference scaling 
(MaxDiff) [16], measuring a set of items on an under-
lying, latent, subjective scale is interested. Thus, this 
case requires a list of items to be measured. In the cur-
rent study, we used a list of items consist of 13 statin-
associated benefit/harm outcomes including moderate 
MI, severe MI, moderate stroke, severe stroke, unstable 
angina, heart failure, liver injury, myopathy, type 2 dia-
betes, acute kidney failure, cancer, nausea/headache, 
and treatment discontinuation due to side-effects. These 
outcomes have been previously selected from RCTs/
meta-analysis by Yebyo et  al. [8] To equally familiarize 
respondents with each of the 13 outcomes, we prepared 
specific clear definitions and short lay descriptions for 
each outcome. To assess whether the short lay descrip-
tions were clear enough for the individuals, we first 
consulted experts in the field to check for their appropri-
ateness. Second, we piloted the lay descriptions with 20 
individuals aged 40–60  years that helped rephrase and 
simplify the medical terms; only some minor changes 
were made in the wording and no substantial revisions 
were required.
The object case BWS method consists of a series of 
choice sets, from the list of items, where respondents are 
asked to select the "best" (or most important) and "worst" 
(or least important) items in each choice set. In the pre-
sent study, the terms "best" and "worst" refer to the most 
and least worrisome clinical outcome, respectively, 
and respondents are asked to indicate the most and the 
least worrisome outcome in each choice set. A balanced 
incomplete block design was used to construct the choice 
sets so that each possible choice was seen the same num-
ber of times through all choice sets, and each choice 
set included the same number of items [19]. Therefore, 
each choice has the same possibility to be chosen as the 
most or least worrisome outcome. This design generated 
13 choice sets with four outcomes in each choice set so 
that each outcome coexisted with another one just once 
(Appendix). An example of BWS questions is given in the 
appendix. A preliminary test with 10 participants was 
conducted to assay the feasibility of the survey design.
Participants and data collection
Participants were selected from the population cov-
ered by primary health care centers in Iran from June 
to November 2019. We decided IraPEN piloted cities 
located in four provinces: Naghadeh in West Azerbaijan, 
Maragheh in East Azerbaijan, Shahreza in Isfahan, and 
Baft in Kerman Province. IraPEN is an Iranian modified 
version of the WHO Package of Essential Noncommu-
nicable Diseases Interventions (WHO PEN). It is a part 
of the national health transformation plan, launched 
in 2014 by the Ministry of Health to provide universal 
health coverage, including access to CVD prevention and 
care [20]. In each city, four urban and four rural health 
centers were randomly selected. In Maragheh, the num-
ber of centers chosen was twice that of the other three 
cities because the population covered by primary health 
care centers was almost twice that of the other areas. We 
planned to recruit 1000 (500 in rural health centers) care-
receivers attending to these health centers.
We recruited the participants using the household 
health files from health centers with a random sam-
pling plan. Participants recruited were 40 years or older 
without a history of CVD events. The study participants 
were interviewed face to face in health centers. First, 
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to familiarize participants with the 13 outcomes, sim-
ple descriptions were presented and asked respondents 
to express their perceived severity using a visual analog 
scale (VAS) for each of the 13 outcomes. We then pro-
vided the choice sets designed using the BWS method. In 
each BWS choice set, the respondent was asked to select 
the most and least worrisome outcome. We asked all staff 
at selected health centers to answer the same question-
naire as well. A total of 172 health care providers from 
urban and rural health centers completed the BWS ques-
tionnaire. All participants signed an informed consent 
form and ethical approval for this study was obtained 
from the Ethics Committee of the Iran University of 
Medical Sciences.
Statistical analysis
We followed the standard analysis of the BWS designs 
and used a counting approach, followed by statistical 
modeling, to analyze data [21]. The counting approach 
calculates several types of scores based on the number 
of times each item was chosen as "best" and the number 
of times chosen as "worst" across participants. To ana-
lyze item importance, we used the average of "Best minus 
Worst (B-W)".
The modeling approach, known as the Maximum-dif-
ference model (logit model), is an expansion of the condi-
tional logit model. This model assumes that respondents 
evaluate all possible pairs of items and choose the pair 
that reflects the maximum difference in preference or 
importance. Under these assumptions, the probability 
of selecting the item "i" as the "best" and item "j" as the 
"worst" expressed as a conditional logit model. In our 
study, each choice set contained four of 13 outcomes. 
Therefore, the number of possible pairs in each choice 
set was 12 pairs. The demographic and clinical charac-
teristics of respondents were reported using descriptive 
statistics. Also, linear regression was used to evaluate fac-
tors, among these characteristics, that affected the prefer-
ences. We used R 3.2.2 and STATA 14.0 for data analyses.
Results
Characteristics of respondents
We invited 1000 care-receivers from 20 urban and 20 
rural health centers. The non-response rate was less 
than 5%, those with a history of CVD were excluded, 
and finally, 913 subjects (449 from urban and 464 from 
rural) were eligible and included in the study. All 172 
invited caregivers participated in the study. The socio-
demographic and other characteristics of participants are 
summarized in Table  1. The mean (SD) age of the total 
participants was 49.8 (8.1) years and 53.2% (n = 486) were 
female. In terms of education, 97% of the general popu-
lation participants were literate and 50% educated in 
middle school or higher (60% in urban and 35% in rural 
areas). Among the general population, 19.6% reported 
that they used statins at the time of study or in the past. 
The mean (SD) age of 172 health care providers was 35.4 
(7.5) years, and 82.5% (n = 142) were female. The health 
care providers’ demographic and clinical characteristics 
were different from those of the general population.
Best‑ worst scaling survey results
The counting analysis results for each group (health care 
provider, total population, and subpopulations) are pre-
sented in Table 2 as total best, total worst, and best minus 
worst (B–W) score for each outcome. According to the 
B–W scores, the most worrisome outcomes were severe 
stroke, sever MI, and cancer, and the least worrisome 
outcomes were myopathy, nausea/headache, and treat-
ment discontinuation.
Figure 1 shows more information regarding the relative 
importance of outcomes among individuals. Based on 
the means of the B-W scores of outcomes as well as their 
standard deviations, severe MI and cancer are similarly 
important, but the variance of cancer is more remarkable 
than severe MI; therefore, the importance of cancer dif-
fers largely among individuals. Moreover, severe stroke 
has a relatively high mean with a relatively low standard 
deviation of the score, which means that the majority 
mark severe stroke as the most problematic outcome. Bar 
plots were drawn from B-W scores to show the heteroge-
neity in more detail (Additional file 1: Figure 2).
Estimates of statin outcome importance, using the VAS 
score (bounded by 0 and 1), are presented in Additional 
file  1: Table  3. Box plots of the BWS scores (on a scale 
from -4 to 4) and the VAS scores (on a scale from 0–1) 
are shown in Fig. 2. The ranking of the 13 outcomes by 
the median of individual BWS was similar to that of VAS. 
However, as the figure depicts, there is less overlap in the 
BWS distributions than the VAS ones and the inconsist-
ency of the scores based on the VAS is broader than that 
based on the BWS.
Table  3 shows the relative importance of the 13 out-
comes associated with statin use estimated by the 
Maximum-difference model. The importance of each 
outcome was assessed relative to the "Myopathy," which 
was consistently rated as the least worrisome outcome. 
The results revealed that severe stroke, sever MI, and 
cancer, which are the most worrisome outcomes of the 
13 outcomes associated with statin use in the general 
population, are approximately 905, 349, and 318 times as 
worrisome as myopathy, respectively (these numbers are 
exponential of the coefficients in Table 3).
Table  4 presents data on self-reported difficulties in 
understanding and compilation of the BWS question-
naire. Most of the participants rated the BWS task 
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Table 1 Characteristics of participants involved in the preference eliciting study
Characteristics Health care provider  
n = 172 N (%)
Total population  
n = 913 N (%)
Urban population  
n = 449 N (%)
Rural population  
n = 464 N (%)
Sex male 30 (17.44) 427 (46.77) 201 (44.77) 226 (48.71)
Female 142 (82.56) 486 (53.23) 248 (55.23) 238 (51.29)
Age mean (SD) 35.37 (7.58) 49.78 (8.148) 50.26 (8.28) 49.31 (7.99)
40–59 172 (100.00) 783 (85.76) 381 (84.86) 402 (86.64)
 = > 60 0 (0) 130 (14.24) 68 (15.14) 62 (13.36)
Education
Non 0 (0) 29 (3.18) 11 (2.45) 18 (3.88)
Primary 10 (5.81) 451 (49.40) 168 (37.42) 283 (60.99)
Middle school 34 (19.77) 272 (29.79) 150 (33.41) 122 (26.29)
High school and above 128 (74.42) 161 (17.63) 120 (26.73) 41 (8.84)
Job
Salaried 159 (92.44) 121 (13.25) 87 (19.38) 34 (7.33)
Run own business 0 (0) 250 (27.38) 99 (22.05) 151 (32.54)
Pensioned 0 (0) 107 (11.72) 67 (14.92) 40 (8.62)
No job 13 (7.56) 435 (47.56) 196 (43.56) 239 (51.51)
Co-living person
Alone 7 (4.07) 18 (1.97) 8 (1.78) 10 (2.16)
Family 165 (95.93) 895 (98.03) 441 (98.22) 454 (97.85)
Morbiditya
None 158 (91.86) 631 (69.11) 300 (66.82) 331 (71.34)
Yes 14 (8.14) 282 (30.89) 149 (33.18) 133 (28.66)
Statin use
no 164 (95.35) 739 (80.94) 356 (79.29) 383 (82.54)
Yes now 4 (2.33) 123 (13.47) 62 (13.81) 61 (13.15)
Yes past 4 (2.33) 51 (5.59) 31 (6.90) 20 (4.31)
Marital status single 39 (22.67) 28 (3.07) 8 (1.78) 20 (4.31)
Married 127 (73.84) 842 (92.22) 425 (94.65) 417 (89.87)
Divorced 5 (2.91) 12 (1.31) 6 (1.34) 6 (1.29)
Widow 1 (0.58) 31 (3.40) 10 (2.23) 21 (4.53)
Family history of heart disease
Yes 41 (23.84) 254 (27.82) 138 (30.73) 116 (25.00)
No 131 (76.16) 654 (71.63) 309 (68.82) 345 (74.35)
Don’t know 0 (0) 5 (0.55) 2 (0.45) 3 (0.65)
Family history of stroke
Yes 11 (6.40) 125 (13.69) 60 (13.36) 65 (14.01)
No 161 (93.60) 784 (85.87) 388 (86.41) 396 (85.34)
Don’t know 0 (0) 4 (0.44) 1 (0.22) 3 (0.65)
Family history of hypertension
Yes 104 (60.47) 518 (56.74) 231 (51.45) 287 (61.85)
No 68 (39.53) 390 (42.72) 215 (47.88) 175 (37.72)
Don’t know 0 (0) 5 (0.55) 3 (0.67) 2 (0.43)
Family history of Hyperlipidemia
Yes 76 (44.19) 291 (31.87) 129 (28.73) 162 (34.91)
No 96 (55.81) 612 (67.03) 316 (70.38) 296 (63.79)
Don’t know 0 (0) 10 (1.10) 4 (0.89) 6 (1.29)
Family history of diabetes
Yes 50 (29.07) 295 (32.31) 152 (33.85) 143 (30.82)
No 122 (70.93) 616 (67.47) 296 (65.92) 320 (68.97)
Don’t know 0 (0) 2 (0.22) 1 (0.22) 1 (0.22)
a Hypertension, Hyperlipidemia, Type 2 diabetes, and Cancer
Page 5 of 11Saadati et al. BMC Med Inform Decis Mak          (2020) 20:288  
as easy-to-understand and easy-to-answer. They also 
reported that answers to all questions were, in a way, 
consistent with their preferences. Participants stated that 
the reasons that influence their choices were "Availabil-
ity of medical care", "Severity of the clinical outcome", 
"Curability of the clinical outcome", "Long-term conse-
quences of the clinical outcome", and "Cost-effectiveness 
of medical services" in order. Also, in the multiple linear 
regression model used to evaluate associations between 
respondent characteristics and choosing an outcome as 
the most worrisome, we did not find any significant asso-
ciation between the factors and the outcome preferred 
(Additional file 1: Table 4).
Discussions
Hypercholesterolemia is a major and modifiable risk fac-
tor for CVD, and medication to lower LDL cholesterol 
is a crucial recommendation for preventing CVD in 
many guidelines. We studied the importance of differ-
ent health outcomes related to statin therapy from the 
health care providers’ and the general population’s per-
spective in urban and rural areas. Each outcome’s quan-
titative weight was derived, showing that the outcomes 
are scored and ranked similarly in various socio-cultural 
contexts.
Statin therapy is the first line of treatment for the pri-
mary prevention of CVD based on the absolute risk [22, 
23]. However, the threshold of absolute risk of CVD over 
ten years has lowered to 7.5–10% for this medication 
[13, 24]. This decrease in the threshold has increased the 
number of people eligible for statin therapy that most of 
them may be healthy and statins may not be appropriate 
for them. Although using statins in individuals at risk can 
prevent cardiovascular disease, there are risks of different 
harm outcomes like muscle pain, increasing serum blood 
sugar, etc. [8]. Assessing relative importance for treat-
ment outcomes is the key step in doing a benefit-harm 
assessment, informed by patient preferences [25].
Patients value different health outcomes at differ-
ent importance. An individual’s preference reflects the 
degree of his/her subjective satisfaction, distress, or 
desirability for a given health outcome [26]. The trade-
offs between different benefits and harms of treatments 
are thus largely influenced by how patients place the rela-
tive importance on each outcome [27].
We found that people without a history of CVD 
events considered some statin-related outcomes more 
worrying than others. Severe stroke, severe MI, and 
cancers were ranked as the most worrisome outcomes, 
while treatment discontinuation, nausea/headache, and 
myopathy were considered the least. There were essen-
tially no differences in the ranking by health care pro-
viders and the general population. Also, we found that 
respondents’ preferences in urban and rural areas were 
similar, despite large differences in the socio-economic 
contexts. These results were the same as the study by 
Yebyo et al. carried out in Ethiopia and Switzerland. [8]. 
They found similar preferences between Ethiopia’s and 
Switzerland’s population with overlapping uncertainty 
intervals. Although more studies in different countries 
are recommended to ensure these results’ generalizabil-
ity, it seems that the preferences are consistent across 
dissimilar settings.
Assessing individuals’ preferences provides valuable 
information in promoting preventive campaigns. There 
has been growing interest in using preference elicitation 
methods to inform health policy and medical decision-
making in recent years [28, 29]. Our results help distin-
guish between more and less worrying outcomes from 
the patients’ perspective and inform decision-making 
on the preventive treatment of individuals with risk for 
cardiovascular events. In this way, quantitative weights 
can be used to calculate a net benefit for statin therapy. 
Yebyo et al. used this kind of weights and found the opti-
mum risk thresholds for statin therapy. For instance, they 
found that at the risk threshold between 12 and 21%, 
depending on age and sex, weighted harms and benefits 
of statin therapy are equal for patients based on their 
own preferences [30].
Although the main economic evaluation method is 
cost-utility analysis, including the standard gamble and 
time trade-off, such an approach is not suitable to find 
trade-offs between health attributes to evaluate cur-
rent practices. Ordinal preference elicitation methods, 
including Discrete Choice Experiments and ranking 
methods, are therefore commonly used in health eco-
nomics and health service research [31]. The BWS is 
relatively simple to understand and reduce the cognitive 
burden for respondents and facilitates the evaluation of 
maximum-difference questions [15]. BWS also over-
comes the traditional ’pick one’ task used in Discrete 
Choice Experiments by eliciting additional information 
on both the most and least preferred option [32]. Addi-
tionally, BWS possesses the ability to embrace a larger 
set of factors to determine preferences [33]. However 
BWS has some limitations such as questions about its 
theoretical foundations, uncertainty about its ability to 
predict consumer choice, getting repetitive for some if 
many objects/attributes, and relatively burdensome to 
some respondents [34].
Compared to the VAS, the BWS is more suitable for 
ranking the outcomes’ relative importance. One advan-
tage of using BWS to elicit preferences is that it allowed 
us to ask patients in a way that they can make trade-offs 
between outcomes [16]. In contrast, there are no trade-
offs involved in VAS tasks when doing it and maybe less 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 7 of 11Saadati et al. BMC Med Inform Decis Mak          (2020) 20:288  
sensitive to detect differences in the outcomes’ scores 
[29]. In other words, most patients can complete BWS 
tasks to express their preferences without major prob-
lems. Our results also showed that VAS is lesser reliable 
with broader distribution in comparison to BWS.
The main limitation in using the BWS method is that a 
different understanding of the outcomes would influence 
eliciting the preferences in this approach [28]. There-
fore, one of the challenges when designing the question-
naire was to ensure that respondents had a common 
understanding of the study outcomes when they were 
doing preference-elicitation tasks. For this purpose, we 
asked respondents to read the short lay descriptions 
for each outcome carefully and complete the VAS tasks 
before they did the BWS tasks. Considering participants 
from health care centers, and not both public and private 
sections, is a limitation in our study. However, we showed 
that individual characteristics, including education and 
job, had no association with their preferences.
Fig. 1 Relationship between the mean Best–Worst score and its standard deviation. The figure depicts the relative importance of the outcomes 
among individuals according to the B–W scores’ means and standard deviations. The higher the mean and lower the variance, the higher and more 
stable the importance ranking
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c d
Fig. 2 Individual best worst scores (BWS) (a, b) and Visual Analog Scales (VAS) (c, d) for the clinical outcomes. The ranking of the 13 outcomes by 
the median of individual BWS was similar to that of VAS. However, as the box plots show, there is less overlap in the BWS distributions than the VAS 
ones and the inconsistency of the scores based on the VAS is broader than that based on the BWS
Table 3 Estimation results of Maximum-difference model. a
a  The coefficients are related to a conditional logit model. The exponential of the coefficients shows the odds ratio of choosing an item as the most worrisome 
outcome compared to choosing the Myopathy as the most worrisome one across all choice sets






Rural population n = 72,384
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI)
Severe stroke 7.85 (7.45–8.23) 6.81 (6.66–6.96) 7.13 (6.90–7.35) 6.58 (6.37–6.78)
Severe MI 6.73 (6.37–7.08) 5.86 (5.72–5.99) 6.06 (5.86–6.26) 5.73 (5.54–5.92)
Cancer 6.62 (6.26–6.97) 5.76 (5.63–5.90) 6.28 (6.07–6.48) 5.34 (5.16–5.52)
Moderate stroke 5.41 (5.08–5.75) 4.52 (4.39–4.65) 4.91 (4.72–5.10) 4.20 (4.03–4.37)
Moderate MI 4.46 (4.13–4.78) 3.69 (3.57–3.82) 4.05 (3.86–4.23) 3.41 (3.25–3.57)
Heart failure 4.11 (3.79–4.42) 3.28 (3.16–3.40) 3.51 (3.33–3.68) 3.11 (2.95–3.26)
Acute kidney failure 4.16 (3.84–4.48) 3.27 (3.15–3.39) 3.58 (3.40–3.76) 3.02 (2.86–3.18)
Type 2 diabetes 3.60 (3.28–3.92) 3.18 (3.06–3.30) 3.32 (3.13–3.50) 3.08 (2.92–3.25)
Liver injury 4.04 (3.72–4.36) 2.93 (2.81–3.05) 3.26 (3.08–3.44) 2.67 (2.51–2.82)
Unstable angina 2.42 (2.15–2.70) 1.94 (1.84–2.05) 2.08 (1.90–2.23) 1.84 (1.70–1.98)
Treatment discontinuation 0.90 (0.67–1.13) 0.80 (0.71–0.90) .90 (0.76–1.04) .72 (0.59–0.85)
Nausea/headache 0.67 (0.44–0.90) 0.36 (0.27–0.46) .30 (0.16–0.44) .42 (0.28–0.55)
Myopathy Ref Ref Ref Ref
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Conclusion
With the preference study results, we know how indi-
viduals consider the trade-offs between treatment ben-
efits and harms. We found that our survey respondents 
consistently ranked severe stroke, severe MI, and cancers 
as the most worrisome outcomes while treatment discon-
tinuation, nausea/headache, and myopathy as the least 
worrisome outcomes. The quantitative weights derived 
here for harms and benefits of statin therapy would be 
beneficial to determine the eligible people for statin ther-
apy, mainly in a policy perspective. Our results showed 
that people from different socio-cultural contexts, rank 
the health outcomes the same way.
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Table 4 Rating of the best–worst scaling exercise
This table presents data on self-reported difficulties in understanding and compilation of the BWS questionnaire regarding different aspects
Variable Items Health care provider Total population
N = 172 % N = 913 %
Questions were easy to understand Strongly agree 92 53.49 248 27.16
Agree 60 34.88 247 52.35
Neither agree nor disagree 9 5.23 147 16.10
Disagree 8 4.65 36 3.94
Strongly disagree 3 1.47 4 0.44
Questions were easy to answer Strongly agree 78 45.35 253 27.71
Agree 70 40.70 503 55.09
Neither agree nor disagree 12 6.98 123 13.47
Disagree 9 5.23 28 3.07
Strongly disagree 3 1.74 6 0.66
Answers were consistent with my preferences Strongly agree 100 58.14 384 42.06
Agree 64 37.21 486 53.23
Neither agree nor disagree 5 2.91 40 4.38
Disagree 3 1.74 3 0.33
Strongly disagree 0 0 0 0
Main reasons for influencing preference for health 
problems
Availability of medical care 41 23.84 285 31.22
Severity of health problems 45 26.16 223 24.42
Curability 34 19.77 134 14.68
Long-term consequences 33 19.19 117 12.81
Cost-effectiveness of medical services 19 11.05 154 16.87
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